Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Investing Activities (2016 - 2025)

Viking Therapeutics' Cash from Investing Activities history spans 11 years, with the latest figure at $75.6 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 1048.42% year-over-year to $75.6 million; the TTM value through Dec 2025 reached $341.4 million, up 161.69%, while the annual FY2025 figure was $341.4 million, 161.69% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $75.6 million at Viking Therapeutics, down from $160.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $160.0 million in Q3 2025 and bottomed at -$459.8 million in Q1 2024.
  • The 5-year median for Cash from Investing Activities is $10.4 million (2021), against an average of -$14.9 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 21018.65% in 2024 before it soared 1048.42% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $27.4 million in 2021, then plummeted by 73.51% to $7.3 million in 2022, then surged by 392.19% to $35.7 million in 2023, then crashed by 81.57% to $6.6 million in 2024, then skyrocketed by 1048.42% to $75.6 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Cash from Investing Activities are $75.6 million (Q4 2025), $160.0 million (Q3 2025), and $42.5 million (Q2 2025).